COPD超额直接成本的20年趋势
基于加拿大不列颠哥伦比亚省行政健康数据,构建2001至2020年医师诊断COPD患者与非COPD个体的回顾性匹配队列,估算超额直接医疗成本。
要点
- COPD患者每人年超额直接医疗成本为5828加元(95%CI 5759-5897)。
- 研究期间COPD超额成本增加48%。
- 合并症相关超额成本为3588加元/人年,其中心血管相关疾病成本超过COPD本身。
核心结论
- 尽管有多方面预防和管理措施,COPD相关经济负担仍在增加,大部分成本归因于合并症。
研究设计与样本
- 利用加拿大不列颠哥伦比亚省行政健康数据,构建医师诊断COPD患者与非COPD个体的回顾性匹配队列,覆盖2001至2020年。
- 通过医院记录、门诊服务、药物和社区护理服务估算直接医疗成本(2020年加元),使用ICD编码评估合并症类别。
- 超额COPD成本为COPD与非COPD队列之间直接医疗成本的调整后差值。
主要发现
- COPD患者每人年直接医疗成本为9224加元,非COPD个体为3396加元,超额成本为5828加元(95%CI 5759-5897)/人年。
- 研究期间超额成本增加48%。
- 合并症导致的超额成本为3588加元(95%CI 3554-3622)/人年。
- 心血管相关疾病单独成本超过归因于COPD的成本(1375加元 vs 904加元/人年)。
临床怎么用
- 临床管理COPD时应重视合并症尤其是心血管疾病的识别与干预,以控制整体经济负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several major risk factors for COPD, such as population ageing, smoking rates and air pollution levels, are rapidly changing, causing inevitable changes in the population burden of COPD. We determined the excess direct costs of COPD and their trend from 2001 to 2020. METHODS: Using administrative health data from British Columbia, Canada, we created a retrospective matched cohort of physician-diagnosed COPD patients and non-COPD individuals. Excess direct medical costs (in 2020 Canadian dollars (CAD)) were estimated by analysing hospital records, outpatient services, medications and community care services. Comorbidity classes were assessed using International Classification of Diseases codes. Excess COPD costs were estimated as the adjusted difference in direct medical costs between the COPD and non-COPD cohorts. RESULTS: There were 208 554 and 404 703 individuals in the COPD and non-COPD cohorts, respectively (47.8% female; mean baseline age 69.1 and 68.2 years, respectively). Direct medical costs for COPD were CAD 9224 per patient-year compared to CAD 3396 per patient-year for non-COPD, giving rise to excess costs of CAD 5828 (95% CI 5759-5897) per patient-year. Excess costs increased by 48% over the study period. Excess costs due to comorbidities were CAD 3588 (95% CI 3554-3622) per patient-year, with cardiovascular-related conditions alone exceeding the costs attributed to COPD (CAD 1375 versus 904 per patient-year). CONCLUSIONS: Despite multifaceted prevention and management initiatives, COPD-related economic burden is increasing, with the majority of costs due to comorbid conditions. Rising per-patient costs, combined with the flat or increasing prevalence of COPD in many jurisdictions, indicates a significant increase in COPD burden.
引用
- Amegadzie JE, Mehareen J, Khakban A, et al. 20-year trends in excess costs of COPD. Eur Respir J. 2025. PMID: 39467610. doi:10.1183/13993003.00516-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。